Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV1001 in mild to moderate Alzheimer's disease
NCT05189210Phase 2Completed
- Sponsor
- GemVax & KAEL Co., Ltd.
- Start
- Oct 2022
- Primary completion
- Apr 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of tertomotide in Alzheimer's disease (AD) (3 arms), sponsored by GemVax & KAEL Co., Ltd. Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 at Week 52. Started Oct 2022; status: completed.
02
Drugs
tertomotide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05189210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05189210.